These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Holmer HK; Keyghobadi M; Moore C; Meshul CK Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485 [TBL] [Abstract][Full Text] [Related]
3. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice. Mori A; Ohashi S; Nakai M; Moriizumi T; Mitsumoto Y Neurosci Res; 2005 Mar; 51(3):265-74. PubMed ID: 15710490 [TBL] [Abstract][Full Text] [Related]
4. Interleukine-1beta and interleukine-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization. Shen YQ; Hebert G; Lin LY; Luo YL; Moze E; Li KS; Neveu PJ J Neuroimmunol; 2005 Jan; 158(1-2):14-25. PubMed ID: 15589033 [TBL] [Abstract][Full Text] [Related]
5. Regulation by D2 dopamine receptors of in vivo dopamine synthesis in striata of rats and mice with experimental parkinsonism. Richard MG; Bennett JP Exp Neurol; 1994 Sep; 129(1):57-63. PubMed ID: 7925842 [TBL] [Abstract][Full Text] [Related]
6. Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice. St-Hilaire M; Bourhis E; Lévesque D; Rouillard C Eur J Neurosci; 2006 Aug; 24(3):795-805. PubMed ID: 16930409 [TBL] [Abstract][Full Text] [Related]
7. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. Haobam R; Sindhu KM; Chandra G; Mohanakumar KP Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598 [TBL] [Abstract][Full Text] [Related]
8. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice. Shepherd KR; Lee ES; Schmued L; Jiao Y; Ali SF; Oriaku ET; Lamango NS; Soliman KF; Charlton CG Pharmacol Biochem Behav; 2006 Mar; 83(3):349-59. PubMed ID: 16580056 [TBL] [Abstract][Full Text] [Related]
9. Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins. Petzinger GM; Fisher B; Hogg E; Abernathy A; Arevalo P; Nixon K; Jakowec MW J Neurosci Res; 2006 Feb; 83(2):332-47. PubMed ID: 16385585 [TBL] [Abstract][Full Text] [Related]
11. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364 [TBL] [Abstract][Full Text] [Related]
12. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195 [TBL] [Abstract][Full Text] [Related]
13. Metabolic changes detected in vivo by 1H MRS in the MPTP-intoxicated mouse. Chassain C; Bielicki G; Keller C; Renou JP; Durif F NMR Biomed; 2010 Jul; 23(6):547-53. PubMed ID: 20661872 [TBL] [Abstract][Full Text] [Related]
14. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115 [TBL] [Abstract][Full Text] [Related]
15. Neonatal exposure to paraquat or MPTP induces permanent changes in striatum dopamine and behavior in adult mice. Fredriksson A; Fredriksson M; Eriksson P Toxicol Appl Pharmacol; 1993 Oct; 122(2):258-64. PubMed ID: 8212007 [TBL] [Abstract][Full Text] [Related]
16. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors. Hill MP; Ravenscroft P; McGuire SG; Brotchie JM; Crossman AR; Rochat C; Millan MJ Mov Disord; 2006 Dec; 21(12):2090-5. PubMed ID: 16991143 [TBL] [Abstract][Full Text] [Related]
17. [The effect of liposomal form of L-Dopa on the level of dopamine, its metabolites, and phospholipid metabolism in the striatum of mice with experimental parkinsonian syndrome]. Iurasov VV; Podgornyĭ GI; Kucherianu VG; Kudrin VS; Nikushkin EV; Zhigal'tsev IV; Sandalov IuG; Kaplun AP; Shvets VI; Kryzhanovskiĭ GN Biull Eksp Biol Med; 1996 Dec; 122(12):614-7. PubMed ID: 9280455 [No Abstract] [Full Text] [Related]
18. Effects of levodopa on striatal monoamines in mice with levodopa-induced hyperactivity. Nicholas AP; Buck K; Ferger B Neurosci Lett; 2008 Oct; 443(3):204-8. PubMed ID: 18657593 [TBL] [Abstract][Full Text] [Related]